32 results about "Ginsenoside Rf" patented technology

The invention provides a radix notoginseng extract which contains 5-10% of notoginsenoside R1, 25-36% of ginsenoside Rg1, 2.5-5% of ginsenoside Re, 30-39% of ginsenoside Rb1, 5-10% of ginsenoside Rd and at least 2% of ginsenoside Rf, ginsenoside Rh1, ginsenoside Rc, ginsenoside Rb2 and ginsenoside Rg3, wherein the ginsenoside R1, the ginsenoside Rg1, the ginsenoside Re, the ginsenoside Rb1 and the ginsenoside Rd account for 75-95% of the total weight. The invention also provides a preparation method of the radix notoginseng extract. The radix notoginseng extract prepared by the method has little impurities, the purity of the component of total saponin is higher, and especially, the components of the ginsenoside Rf, the ginsenoside Rh1, the ginsenoside Rc, the ginsenoside Rb2, the ginsenoside Rg3 and the like with very low content are purified. The medicinal preparation prepared by the radix notoginseng extract has better curative effect and higher safety.

The invention provides a medicinal composition, which comprises the following components: ginsenoside Rb1, ginsenoside Rg1, notoginsenoside R1, ginsenoside Rd, ginsenoside Re, ginsenoside Rf, ginsenoside Rc, ginsenoside Rh1, ginsenoside Rb2 and ginsenoside Rg3. The invention also provides a preparation method for the medicinal composition. The medicinal composition has definite components; compared with the total notoginsenoside in the prior art, the medicinal composition has stable quality and good controllability; and results of experiments of acute toxicity, undue toxicity, hemolysis and the like show that the medicinal composition has higher safety and wide clinical application prospect.

The present invention discloses a UPLC-MS quantitative method for the contents of twelve components in a traditional Chinese medicine composition preparation, specifically determination of the contents of calycosin-7-O-beta-D-glucoside (1), isoquercitrin (2), narirutin (3), hesperidin (4), ginsenoside Re (5), ginsenoside Rg1(6), periplocoside (7), ginsenoside Rf (8), ginsenoside Rb1 (9), astragaloside (10), ginsenoside Rd (11) and periplocin H1 (12) in the traditional Chinese medicine composition, and belongs to the field of traditional Chinese medicine composition preparation component detection. The determining method of the present invention has characteristics of short period, good reproducibility and high sensitivity.

The invention provides a method for measuring content of five saponin components in red ginseng roots. Ginseng saponin components of main effective active components of the red ginseng roots and are important standards measuring advantages and disadvantages of inner quality of the red ginseng roots. According to the method, ginseng saponin Rg1, ginseng saponin Re, ginseng saponin Rf, ginseng saponin Rb1 and ginseng saponin Ro in the red ginseng roots are simultaneously measured by the aid of an ultra-high performance liquid chromatography, and the method is high in sensitivity, accurate and reliable and can be used for controlling quality of the red ginseng roots.

The invention provides a panax notoginseng saponin composition and a preparation method and application thereof.The composition is prepared from, by weight, 30-50% of ginsenoside Rg1, 25-40% of ginsenoside Rb1, 7-16% of notoginsenoside R1, 2.7-8% of ginsenoside Re, 0.5-7.0% of ginsenoside Rd, 0.5-2% of ginsenoside Rf, 0.3-2.0% of ginsenoside Rh2, 1-3% of ginsenoside Rc, 0.3-2.5% of ginsenoside Rb3 and 0.5-2.5% of ginsenoside Rg3, wherein ginsenoside Rg1, ginsenoside Rb1 and notoginsenoside R1 account for 70-95% of the total weight of the active components, and the sum of the contents of ginsenoside Rb1 and notoginsenoside R1 is not smaller than 8 times of the content of ginsenoside Rd.Compared with commercially available Xueshuantong injections and Xueshuantong preparations, the panax notoginseng saponin composition has a more obvious arterial and venous thrombosis resistant effect, low toxicity and high safety.

The invention provides a detection method of a ginseng/pseudo-ginseng-containing traditional Chinese medicine preparation. The method comprises the following steps: (1) taking a ginseng/pseudo-ginseng-containing traditional Chinese medicine composition or traditional Chinese medicine preparation, and preparing a test sample solution; (2) taking a ginseng/pseudo-ginseng-free finished product, and preparing a negative sample solution; (3) taking a ginsenoside Rb1 reference substance, a ginsenoside Re reference substance, a ginsenoside Rg1 reference substance, a ginsenoside Rf reference substance and a pseudo-ginseng saponin R1 reference substance, respectively adding methanol to prepare a mixed solution containing 0.5-2mg of respective reference substance per 1ml as a reference substance mixed solution; (4) detecting; and (5) analyzing the result. The method can simultaneously indentify ginseng and pseudo-ginseng, and simultaneously identify the index components ginsenoside Rb1, ginsenoside Re, pseudo-ginseng saponin R1, ginsenoside Rf and ginsenoside Rg1. The detection method is simple and easy to implement, and has the characteristics of high specificity and favorable repetitiveness.

The invention discloses a method for determining contents of seven types of ginsenosides in healthcare food. The seven types of ginsenosides are Rg1, Re, Rc, Rf, Rb1, Rb2 and Rd. The method comprises the steps of: (1) preprocessing a sample; (2) carrying out chromatographic analysis by using a reversed-phase high performance liquid chromatography column; (3) detecting by using an Ultraviolet (UV) detector; (4) determining the compositions of the ginsenosides in the sample according to the retention time of a chromatographic peak; and (5) determining the content of the ginsenosides in the sample by using an external standard method. By means of the method disclosed by the invention, the defects of the traditional detection technology are overcome, the determination of the ginsenoside RF is enhanced, the content of the ginsenosides in the healthcare food can be better analyzed, a basis for better judging American ginseng and ginseng can be provided, and the blank regard to the subject in relevant standards in China is made up.

The invention discloses a red ginseng extract. The extract is characterized by containing ginsenoside Rg1, ginsenoside Re, ginsenoside Rf, notoginsenoside R2 and ginsenoside Ro. A preparation method of the extract comprises the following steps: cutting red ginseng serving as a medicinal material into pieces, adding water in an amount which is 3-10 times that of the red ginseng, soaking for 0.5-2 hours, heating and performing reflux extraction for 1-2 hours, extracting for 1-3 times, combining extraction solutions, filtering and concentrating; separating and purifying a concentrated solution with a reverse phase silica gel column; eluting with 30-40 percent methanol-water by 4-10L, and discarding; and eluting with 50-70 percent methanol-water by 4-6L, collecting an eluent and concentrating to obtain active ingredients.

The invention relates to a group of high-activity glycosyl transferases responsible for sugar chain extension and an application of the glycosyl transferases. Specifically, the invention provides glycosyl transferase and a derivative polypeptide thereof, which can efficiently catalyze the reaction of extending sugar chains on the first glycosyl at the C-20 site and the first glycosyl at the C-6 site of a tetracyclic triterpenoid substrate. The ginsenoside products such asginsenoside Rb1, the ginsenoside Rb3, the ginsenoside DMGG, the ginsenoside DMGX, the gynostemma pentaphyllum saponin LXXV, the gynostemma pentaphyllum saponin XVII, the gynostemma pentaphyllum saponin XIII, gynostemma pentaphyllum saponin IX, notoginsenoside U and the notoginsenoside R1, notoginsenoside R2, notoginsenoside R3, 3-O-beta-(D-xylopyranosyl)-beta-(D-glucopyranosyl)-CK, 20-O-glucosyl ginsenoside Rf, Rd-C20-O-Rha, ginsenoside Rg2, and ginsenoside Re and the like can be obtained. The glycosyl transferase disclosed by the invention can also be applied to construction of artificially synthesized ginsenoside and a plurality of new ginsenosides and derivatives thereof.

The invention relates to the field of medicine, specifically relates to the new application of ginsenoside Rf, and in particular relates to the application of the ginsenoside Rf serving as a TRPV1 antagonist. The antagonist ginsenoside Rf is capable of remarkably inhibiting TRPV1 protein expression at the cellular level, and at the animal level, is capable of remarkably prolonging the paw withdrawal latency of a rat induced by capsaicin (CAP) and reducing the degree of sensitivity of the rat to pain. As a result, the ginsenoside Rf can be used as the TRPV1 antagonist to ease pain with TRPV1 as the target spot, and also can be used for preparing analgesics for treating diseases related to a TRPV1 receptor.

The invention provides a method for determining the content of ginsenoside in a panax traditional Chinese medicine, which adopts an ultra-high performance liquid chromatography electrospray detector method to simultaneously determine the content of 15 kinds of ginsenoside in the panax traditional Chinese medicine. The 15 kinds of ginsenoside comprise notoginsenoside R1, ginsenoside Rg1, ginsenoside Re, 24 (R)-pseudoginsenoside F11, ginsenoside Rf, ginsenoside Ra2, ginsenoside Rb1, ginsenoside Rc, ginsenoside Ro, ginsenoside Rb2, ginsenoside Rb3, panax japonicus saponin IV, ginsenoside Rd, panax japonicus saponin IVa and 20 (R)-ginsenoside Rg3. By adopting the method disclosed by the invention, the contents of 15 kinds of ginsenoside in various panax traditional Chinese medicines can be simultaneously determined by reasonably selecting chromatographic conditions and detection conditions, and the method has the advantages of simplicity, convenience, accuracy, high sensitivity, strong specificity and the like, so that the method can be credibly, comprehensively and accurately used for quality control of the panax traditional Chinese medicines.

The invention relates to the field of radix notoginseng pharmaceutical analysis, in particular to a construction method for HPLC (High Performance Liquid Chromatography) fingerprints of a radix notoginseng medicinal material and panax notoginseng saponins. The construction method comprises the following steps: (1) weighing a proper amount of notoginsenoside R1, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3 and ginsenoside Rf control substances, and adding methanol for dissolving to obtain a mixed control substance solution of which the concentration is 30 to 70 mu g.mL; (2) weighing a radix notoginseng sample, placing the weighed radix notoginseng sample into a container, adding the methanol to prepare a solution of which the concentration is 30 to 50 mu g.mL, weighing, performing ultrasonic extraction for 30 to 60 minutes, cooling to room temperature, supplementing lost solvent by the methanol, and filtering an extraction solution with a microfiltration membrane to obtain a test solution; (3) performing high performance liquid chromatography analysis on the mixed control substance solution obtained in step (1) and the test solution obtained instep (2) respectively; (4) testifying chemical components in a fingerprint with a control substance control method by adopting LC-MS (Liquid Chromatograph-Mass Spectrometer) or an HPLC-MS to constructthe HPLC fingerprint of the radix notoginseng medicinal material. The method can be applied to and provides a basis for the quality analysis of the radix notoginseng medicinal material and total saponin extracts.

The present invention relates to a composition containing, as an active ingredient, gincenoside RF, for providing effects such as improvement of acne and skin troubles, skin clearing, pore tightening, in addition to providing effects such as skin tone improvement, hair growth promotion, improvement of graying hair, anti-dandruff, and antisepsis.

The invention discloses a method for determining the contents of multi-index components in Weifuchun tablets, which comprises the following steps: step 1, preparing a mixed reference substance solution: precisely weighing reference substances of hesperidin, neohesperidin, rosmarinic acid, ginsenoside Re, ginsenoside Rg1, ginsenoside Rf and ginsenoside Rb1, and dissolving the reference substances in methanol to prepare the mixed reference substance solution; step 2, carrying out preparation of a test solution: taking a Weifuchun tablet sample, performing grinding, precisely performing weighing, and adding the product into a methanol solution to prepare a test solution; and step 3, carrying out determination: respectively taking the mixed reference substance solution obtained in the step 1 and the test solution obtained in the step 2, performing quantitative sample introduction, and performing determination by adopting a UPLC-QDa coupling technology. The UPLC-QDa multi-index component content determination method established by the invention is used for determining 14 batches of Weifuchun tablets sold in the market. The result shows that the method can be used for evaluating the consistency between batches of the Weifuchun tablets and the controllability of the process, the quality of the Weifuchun tablets can be comprehensively controlled, and a reference is provided for improving the quality of the Weifuchun tablets.

The invention provides a serratia marcescens HGS-487 strain for converting ginsenoside Rf into ginsenoside Rg1. The strain is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China; the postcode is 430072, the preservation date is December 17, 2019, and the preservation number is CCTCC NO: M20191057; and the 16SrDNA sequence of the strain is as shown in SEQ ID NO. 1. The serratia marcescens HGS-487 strain can be used for preparing ginsenoside Rg1 through fermentation and conversion.

The invention provides a rahnella HGS-393 strain for converting prototype ginsenoside Rf into rare ginsenoside Rh1. The strain is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China; the postal code is 430072, the preservation date is May 7, 2021, and the preservation number is CCTCC NO: M2021498. The 16S rDNA sequence of the strain is as shown in SEQ ID NO. 1. The rahnella HGS-393 strain can be used for preparing the rare ginsenoside Rh1 through fermentation and conversion.